UK pension risk transfer is projected at £70 billion for 2026, yet the buyout market cannot absorb the largest defined benefit plans. Longevity swaps fill that gap: they transfer mortality risk without moving assets or triggering settlement accounting. WTW projects up to £20 billion in UK longevity swap volume for 2026 (WTW, January 2026).

£20B
UK longevity swap volume anticipated for 2026, up from prior years, per WTW projection
£6B
BBC Pension Scheme longevity swap with Zurich and MetLife, November 2025, covering 21,000 members
$48.7B
US pension risk transfer volume in 2025, the market into which longevity swaps are now expanding (Aon)

The Capacity Ceiling in the Buyout Market

The UK bulk annuity market's record ambitions create an inherent structural constraint. LCP projects £40-55 billion in UK buy-in volume for 2026, potentially surpassing the 2023 record of £49.1 billion (LCP, November 2025). WTW's estimate for total UK pension risk transfer reaches £70 billion. Both figures assume that insurer capital and asset origination pipelines can absorb the volumes, and for plans in the £500 million to £5 billion range, that assumption holds. For plans carrying £15 billion or more in liabilities, it does not.

A single £15 billion buyout transaction requires the purchasing insurer to hold regulatory capital against the full annuity portfolio under Solvency II, originate matching assets, typically illiquid credit, infrastructure debt, and private placements, to meet the matching adjustment requirements, and manage the operational complexity of converting an entire scheme to direct annuity payment for potentially tens of thousands of members. No single UK bulk annuity insurer has executed a buyout at that scale in a single transaction. The constraint is not a temporary shortage; it is a structural feature of how insurance regulatory capital and asset origination work.

For US plans, the same dynamic applies at a different threshold. Aon reported approximately $48.7 billion in US pension risk transfer transactions for 2025 across the full market (Aon, 2025). A $10 billion US pension plan seeking a full buyout would need to find a carrier willing to absorb roughly 20 percent of annual market volume in a single deal at competitive pricing. No carrier routinely quotes at that level of concentration. The de-risking need is real; the buyout market simply cannot meet it at scale for the very largest plans.

Fixed Leg, Floating Leg, and How Longevity Swap Cash Flows Actually Work

A longevity swap is a bilateral contract between a pension plan and an insurer or reinsurer that transfers mortality risk without transferring the plan's investment assets. The structure rests on two settlement legs calculated against an agreed reference population and improvement model.

The fixed leg is the stream of expected benefit payments derived from a mortality table and improvement scale locked in at inception. These payments represent what the plan projected it would pay based on the actuarial assumptions embedded at execution: the reference mortality curve, the agreed improvement factors, and the demographic data submitted at closing. The counterparty pays this fixed stream to the plan on each settlement date.

The floating leg is the stream of actual benefit payments made to members in the reference population during each settlement period. The plan pays this actual stream to the counterparty. Settlement is typically quarterly or semi-annual: the two streams are netted, and one party pays the difference.

The directional logic is straightforward. When members live longer than the reference table projected, actual benefit payments exceed the fixed leg, and the counterparty pays the excess to the plan. When mortality is heavier than expected, actual payments fall below the fixed leg, and the plan pays the counterparty the difference. Across any given quarter, the settlement amount is the net present value of actual versus expected benefit payments for the covered cohort.

What the swap does not transfer is equally important. The plan's investment portfolio stays in place. The investment management agreement is unaffected. The plan's funding level, contribution schedule, actuarial valuation, and relationship with the sponsor continue unchanged. No settlement accounting under ASC 715 (US) or FRS 102 (UK) is triggered. The plan remains the benefit obligor; it has simply hedged the cost of that obligation against the uncertainty of how long members will live. For a plan carrying £15 billion in liabilities, that structural distinction is the difference between a feasible transaction and a decade-long wait for buyout market capacity to catch up.

The Reinsurance Chain Behind Every Longevity Swap

Direct longevity swap counterparties, the insurers who face the pension plan, rarely retain the full mortality tail on their own balance sheets. They cede longevity exposure to specialist reinsurers who aggregate and manage portfolios of longevity risk across multiple geographies and cohorts, offsetting their own mortality book in the process.

In the UK, the established reinsurance counterparties for longevity risk include Canada Life Reinsurance, Pacific Life Re, Munich Re, RGA, and Swiss Re. Legal & General operates on both sides of the market, retaining some longevity exposure directly and ceding the rest into the reinsurance market. The BBC Pension Scheme's November 2025 transaction illustrates the layered structure precisely: Zurich Assurance served as the primary counterparty facing the scheme, while MetLife assumed the reinsurance risk behind Zurich, covering approximately £6 billion in liabilities across 21,000 members (MetLife, November 2025). That transaction extended the scheme's £3 billion 2020 longevity swap with the same counterparty structure, meaning nearly all of the BBC scheme's pensioner and dependant liabilities are now hedged against longevity risk.

The European market has seen additional activity in 2025. Pacific Life Re completed a EUR 2 billion longevity swap reinsurance agreement with Nationale-Nederlanden Life in February 2025, adding to its growing European longevity reinsurance book. Canada Life Reinsurance maintains a dedicated longevity reinsurance practice with active capacity across the UK, Canada, and Ireland.

In the US, Munich Re North America Life launched an explicit longevity reinsurance product for the US and Canada market in September 2024, describing it as a mechanism for insurers to "convert uncertain future pension or annuity payments into a fixed cash flow stream, locking in mortality assumptions and a fee at inception" (Munich Re, September 2024). That launch signals a deliberate push to expand US longevity swap counterparty capacity beyond the historically UK-concentrated reinsurance flow. With Munich Re now participating alongside Prudential, MetLife, and a handful of other carriers, the US market's reinsurance depth is materially broader than it was 18 months ago.

The reinsurance chain matters for plan actuaries because the pricing embedded in the fixed leg must be consistent with what the primary insurer can reasonably cede. The reinsurer's capital strength, mortality expertise, and portfolio diversification ultimately determine whether competitive pricing is sustainable at large transaction sizes. Counterparty credit quality, not just the primary insurer's but the reinsurer's, becomes a risk dimension the plan actuary must evaluate before execution.

UK Market in 2026: £20 Billion and the Plans Driving It

With WTW projecting up to £20 billion in UK longevity swap volume for 2026, the instrument is no longer a niche transaction executed by a handful of the very largest schemes. The BBC deal at £6 billion now represents one transaction in a market where activity is broadening, reinsurer capacity from Munich Re, Canada Life Reinsurance, and Pacific Life Re is actively growing to meet demand, and schemes are increasingly treating longevity swaps as a first-phase de-risking tool rather than an alternative to eventual buyout.

LCP's 2026 PRT predictions note that longevity risk transfer will be driven by large schemes but that smaller schemes are showing growing interest in longevity swaps as a pre-buyout positioning tool. The broader UK pension de-risking landscape, tracking toward £70 billion in total risk transferred to insurers and reinsurers in 2026, has reached a scale where the largest schemes can no longer passively wait for buyout capacity to grow to match their liabilities.

The UK's consolidation context reinforces the urgency. Three of the eleven bulk annuity insurers active in the market announced acquisitions in 2025: Pension Insurance Corporation by Athora, Just Group by Brookfield, and Utmost's life and pensions division by JAB Insurance, with all three expected to complete in H1 2026. As analyzed in our coverage of the UK pension buyout boom and its three insurer transactions, consolidation changes the competitive landscape for buyout pricing in ways that are not yet fully visible. Schemes locking in a longevity swap now secure the mortality hedge independently of how post-consolidation insurer dynamics evolve.

Basis Risk: The Actuarial Cost of Demographic Mismatch

The longevity swap's core attraction, transferring mortality risk without asset transfer, comes with a technical cost that makes the actuarial setup more demanding than a buyout. That cost is basis risk: the divergence between the plan's actual member mortality experience and the reference population embedded in the fixed leg.

Every longevity swap is written against a reference table agreed at inception. In UK swaps, the reference population is typically drawn from the S-series insured pensioner life tables (such as S1PMA for male pensioners or the PNXA 08 tables for broader annuitant populations), combined with the CMI mortality improvement model. In US transactions, the SOA's mortality improvement scale MP-2021 provides the foundational projection, calibrated to Social Security Administration and NCHS population data through 2019 (SOA, October 2021).

The problem is that no standard reference table perfectly matches a specific plan's membership. A plan with a high concentration of manual workers in heavy industry will experience materially heavier mortality than the S1PMA population suggests. A plan with a predominantly white-collar, higher-income membership will experience lighter mortality. The divergence between actual plan mortality and the reference table does not average out over time; it is a systematic feature of the plan's demographic composition. Basis risk is the unhedged residual that remains after the swap is in place.

When basis risk produces consistent settlement mismatches over multiple years, the aggregate effect on a very large plan is significant. For a plan with £15 billion in liabilities, a systematic divergence of even a few basis points in annual mortality improvement translates into tens of millions of pounds in unhedged exposure per year. Actuaries structuring large longevity swaps spend considerable effort on reference population selection, member data cleansing, and socioeconomic classification analysis to narrow the basis risk before execution.

RGA's research on US mortality improvements and DB pension populations has documented that the relationship between a plan's membership and the general population is systematically material: DB pensioners are not the general population, and relying on general population improvement rates overstates or understates actual improvement for a specific pensioner group depending on the plan's occupational and income composition. That finding applies equally to the MP-2021 scale, which is calibrated to the national population rather than the DB pensioner subset.

CMI 2024 and SOA MP-2021: Reference Frameworks with Structural Differences

The UK and US mortality projection models share a common architecture but diverge in structure and recent calibration in ways that directly affect longevity swap pricing on each side of the Atlantic.

The Continuous Mortality Investigation's CMI 2024 model, the current standard for UK pension scheme mortality projections, projects mortality improvements by interpolating between recent historical improvements and an assumed long-term rate. Moving from CMI 2023 to CMI 2024 increases projected life expectancy by approximately three months for males and one month for females at age 65, a change that flows directly into the fixed leg calculation of any UK longevity swap executed under the new model (CMI, 2025). Counterparties price to the current model; plans with swaps written under CMI 2021 or CMI 2022 carry a model-basis mismatch relative to current market assumptions, a mismatch that narrows as actual mortality data accumulates over the swap's life.

The SOA's MP-2021 applies a more flexible fitting structure than the CMI model. Where CMI imposes a rigid age-period-cohort decomposition on historical improvements, the SOA's Mortality Improvement Model (MIM-2021) fits historical improvements with greater flexibility and applies convergence periods that do not vary by age, while CMI's convergence periods do vary by age and can be longer or shorter than MIM-2021 at different points in the age distribution. In practice, a UK longevity swap executed against CMI 2024 and a US longevity swap executed against MP-2021 are building in structurally different assumptions about how quickly current improvement rates converge to long-term trend, which affects the fair value of the fixed leg and the pricing spread over the expected mortality curve.

Actuaries valuing longevity swaps in cross-border reinsurance structures, where a UK primary insurer cedes to a US or Bermuda reinsurer, must reconcile these model differences explicitly. The reference population and improvement model are both negotiated at execution; the actuarial team advising the pension plan needs to understand the pricing implications of each choice, not just select from a menu.

The Pre-Buyout Hedge: Sequencing a Longevity Swap Before the Termination

The most strategically sophisticated use of the longevity swap is as a positioning tool ahead of an eventual full buyout. A plan executing a longevity swap today hedges the actuarial uncertainty around long-term mortality experience for the covered cohort. When the plan approaches the buyout market in three to seven years, the remaining liability pricing uncertainty has been narrowed: the insurer quoting on the buyout has access to years of settled swap data and can price against a population whose mortality behavior is now partially observed rather than purely projected from a table.

That track record has direct pricing value. Buyout pricing is fundamentally an insurance company's view of the plan's mortality risk. A plan presenting five years of quarterly longevity swap settlements, showing that actual member mortality tracks the reference table within a defined range, enters the buyout negotiation on stronger informational footing than a plan presenting only a raw actuarial valuation. The swap creates evidence about the plan's specific mortality, reducing the actuarial uncertainty load that carriers embed in their buyout pricing margins.

The sequencing also addresses the market capacity constraint in a more direct way. The buyout market's ability to absorb very large transactions is constrained in any given year by insurer capital and asset origination pipelines, as explored in detail in our analysis of pension risk transfer bid economics on standard versus complex populations. A plan executing a longevity swap now reduces its unhedged liability footprint without requiring buyout market access at all. When conditions are favorable, a specific combination of funded status, annuity purchase pricing, and insurer capacity, the remaining buyout transaction is sized against a population whose mortality is partially hedged, potentially making it feasible for a single carrier to quote competitively where it could not before.

The Milliman 100 Pension Funding Index's year-end 2025 aggregate surplus of $98 billion and a 108.1 percent funded ratio (Milliman, January 2026) represent the ideal conditions for executing this sequencing. Plans that are well-funded today face a specific risk: a funded status reversal driven by an equity drawdown or interest rate decline closes the de-risking window before the longevity hedge is in place. Executing the swap now, while assets comfortably exceed liabilities, hedges the mortality tail without committing the full plan to a termination that could be disrupted by an interim market shock.

Capital, Regulation, and the Actuarial Agenda

Two regulatory developments are reshaping the capital and pricing economics of longevity swaps in ways pension actuaries need to track through 2026 and 2027.

The NAIC Longevity Risk (E/A) Subgroup is finalizing a C-2 RBC charge that separates retained and ceded longevity exposure within insurers' risk-based capital calculations, with a year-end 2027 target effective date. As detailed in our analysis of the NAIC C-2 longevity risk RBC framework, the structure includes counterparty factor tables for ceded longevity risk and a retained scenario stress that will increase required capital for insurers holding longevity exposure directly. For US counterparties writing longevity swaps or longevity reinsurance, the new charge directly affects the capital required to back the position, and that capital cost will flow through into pricing once the framework takes effect. Plans considering US longevity swap executions have a window before 2027 in which current pricing does not yet fully reflect the new regulatory capital regime.

The IRS's 2027 DB mortality table update, which the SECURE 2.0 Act requires to reflect more current mortality data, will also affect the liability baseline against which longevity swaps are priced. Our coverage of the 2027 DB mortality table mechanics showed that updated tables tend to reduce minimum required contributions slightly (as lives are projected to be slightly shorter by some measures in recent data) while also narrowing the gap between the plan's actuarial liability and the annuity purchase cost. Plans that have already executed longevity swaps written against older mortality bases will need to assess whether the table change creates a new layer of basis risk between the swap reference population and the current actuarial assumption.

Taken together, the market signals point in one direction. The largest defined benefit plans, those above $5-10 billion in US liabilities or £5-15 billion in UK liabilities, are not well-served by waiting for the buyout market to develop capacity at their scale. The longevity swap addresses the part of the liability that is hardest to price and most volatile over long time horizons. The actuarial work to execute one well, selecting the right reference population, quantifying and managing basis risk, understanding the reinsurance chain, and sequencing the swap as a pre-buyout hedge, is demanding precisely because the instrument transfers real mortality risk. That is also why it works.

Further Reading

Sources